1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hepatitis B, C, and D virus and human T-cell leukemia virus types 1 and 2 infections and correlates among men who have sex with men in Ouagadougou, Burkina Faso

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Men who have sex with men (MSM) are considered to be at significant risk for sexually transmitted infections (STI) and bloodborne viruses including viral hepatitis types B, C, and D (HBV, HCV, and HDV) and human T-cell leukemia virus types 1 and 2 (HTLV 1&2). This study aimed to assess the seroprevalence and correlates of HBV, HCV, HDV, and HTLV 1&2 antibodies among MSM in Ouagadougou, Burkina Faso.

          Methods

          We conducted a cross-sectional survey to assess the biological and behavourial characteristics among MSM in Ouagadougou from January to April 2013. Serum specimens obtained were tested for the presence of HBV, HCV, HDV and HTLV-1&2 infections. MSM 18 years and older were recruited using respondent driven sampling (RDS). Population estimates and 95% confidence intervals (CI) adjusted for the RDS design were calculated using RDS Analysis Tool (RDSAT) version 6.0.1 (RDS, Inc., Ithaca, NY). Bivariate and multivariate logistic regression analyses were conducted to assess correlates of these infections using Stata 14.

          Results

          A total of 329 MSM were tested. Prevalence was 20.4% (95% CI: 16.4–25.1) for HBV, 11.0% (95% CI: 8.0–14.8) for HCV, and 0.0% for HDV. Anti-HTLV 1&2 antibodies were found in 4.0% (95% CI: 2.3–6.8) of MSM. Factors independently associated with HBV infection were lack of condom use during the last anal sex act with a main male sexual partner and experience of condom tearing during anal sex. Presence of anti-HTLV 1&2 antibodies was associated with history of genital or anal lesions and injection drug use. None of the variables included in our study were associated with HCV.

          Conclusions

          This study shows that HBV, HCV and HTLV 1&2 prevalence among MSM in Burkina is high and suggests that comprehensive STI prevention and sexual health education services for this group are needed.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease.

          Integration of hepatitis B vaccination into national immunization programs has resulted in substantial reductions of hepatitis B virus (HBV) transmission in previously high endemic countries. The key strategy for control of the HBV epidemic is birth dose and infant vaccination. Additional measures include use of hepatitis B immunoglobulin (HBIG) and diagnosis of mothers at high risk of transmitting HBV and use of antiviral agents during pregnancy to decrease maternal DNA concentrations to undetectable concentrations. Despite the substantial decrease in HBV cases since vaccination introduction, implementation of birth dose vaccination in low-income and middle-income countries and vaccination of high-risk adults remain challenging.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Global estimates of prevalence of HCV infection among injecting drug users.

            In this paper, we review evidence of HCV prevalence among injecting drug users (IDUs) worldwide. We undertook a desk-based review of both 'grey' and published literature released between 1998 and 2005. Data on HCV prevalence among IDUs was found in 57 countries and in 152 sub-national areas. We found reports of HCV prevalence of at least 50% among IDUs in 49 countries or territories. Available regional estimates varied widely, from 10 to 96% in Eastern Europe and Central Asia, from 10 to 100% in South and South-East Asia, from 34 to 93% in East-Asia and the Pacific, from 5 to 60% in North Africa and the Middle-East, from 2 to 100% in Latin America, from 8 to 90% in North America, from 25 to 88% in Australia and New Zealand, and from 2 to 93% in Western Europe. Only in Colombia and Lebanon were all HCV prevalence estimates below 20%. In addition, evidence of HIV/HCV co-infection among IDUs was found in 16 countries. In China, Poland, Puerto Rico, Russia, Spain, Switzerland, Thailand and Viet Nam, estimates of the prevalence of HIV/HCV co-infection among IDUs reached 90%. Taken together, data suggest high global prevalence of HCV and HIV/HCV co-infection among IDUs. We suggest exploring protective factors in sites of low HCV prevalence.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa.

              Hepatitis C virus (HCV) is a major cause of chronic liver disease in the world. The WHO estimates that 3% (170 million) of the world's population are chronically infected with HCV. Sub-Saharan Africa is of great interest because it is reported to have the highest HCV prevalence rate (5.3%), and a concurrent HIV epidemic. In our review of the published literature we found consistent evidence of high HCV prevalence in many countries of Africa. We estimate the overall prevalence of HCV in Sub-Saharan Africa is 3.0%. The central African region has the highest estimated prevalence of 6%, west Africa has an estimated prevalence of 2.4%, and southern and east Africa with the lowest estimated prevalence of 1.6%. Given low sexual transmission of HCV and infrequency of intravenous drug use in Sub-Saharan Africa, iatrogenic causes of HCV transmission need to be further evaluated.
                Bookmark

                Author and article information

                Contributors
                gouedraogo@irss.bf , whgautier@yahoo.fr
                skouanda@irss.bf
                grossoas@gmail.com , agrosso@healthsolutions.org
                rebecca23fr@yahoo.fr
                modibocamara2000@yahoo.fr
                charlemagne_dabire@yahoo.fr
                rama.ouedtra@univ-ouaga.bf
                ytraore@yahoo.com
                sbaral@jhu.edu
                barronicolas@yahoo.fr
                Journal
                Virol J
                Virol. J
                Virology Journal
                BioMed Central (London )
                1743-422X
                29 December 2018
                29 December 2018
                2018
                : 15
                : 194
                Affiliations
                [1 ]ISNI 0000 0004 0564 0509, GRID grid.457337.1, Biomedical and Public Health Department, , Institut de Recherche en Sciences de la Santé (IRSS), ; Ouagadougou, 03BP7192 Burkina Faso
                [2 ]University Ouaga1 Joseph Ki-Zerbo, Ouagadougou, Burkina Faso
                [3 ]Institut Africain de Santé Publique, Ouagadougou, Burkina Faso
                [4 ]ISNI 0000 0001 2171 9311, GRID grid.21107.35, Department of Epidemiology, , Johns Hopkins Bloomberg School of Public Health, ; Baltimore, MD USA
                Author information
                http://orcid.org/0000-0001-8566-7530
                Article
                1110
                10.1186/s12985-018-1110-8
                6311018
                30594218
                8bae27c3-4d9b-434c-b837-50592e4aa4fc
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 6 August 2018
                : 19 December 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000200, United States Agency for International Development;
                Award ID: GHH-I-00-0700, 032-00, supported by the USA President's Emergency Plan for AIDS Relief
                Award Recipient :
                Funded by: Institut de Recherche en Sciences de la Santé (IRSS)
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Microbiology & Virology
                hbv,hcv,hdv,htlv 1&2,msm,burkina faso,west africa
                Microbiology & Virology
                hbv, hcv, hdv, htlv 1&2, msm, burkina faso, west africa

                Comments

                Comment on this article